|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | China National Medical Products Administration approval summary:anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy显示文摘Background:On May 8,2018,the China National Medical Products Administration(NMPA)approved anlotinib,an orally administered anti-angiogenesis inhibitor,for the treatment of patients with advanced non-small cell lung can-cer(NSCLC)who have progressed after treatment with two or more lines of prior systemic chemotherapy.Main body of the abstract:China NMPA reviewed and inspected a regional double-blinded,placebo-controlled,Phase III trial comparing the overall survival(OS)of NSCLC patients between the anlotinib and placebo arms.A total of 437 patients were randomized(2:1)to receive either anlotinib(n=294)or placebo(n=143)once daily on a 2-week on and 1-week off schedule.Patients with epidermal growth factor receptor(EGFR)or activating anaplastic lymphoma kinase(ALK)genomic tumor aberrations should have disease progression on NMPA-approved therapy.Anlotinib is the first NMPA-approved drug for patients with advanced NSCLC who have progressed on at least two lines of prior systemic chemotherapies in China.The approval was based on a statistically and clinically significant improvement in median OS with anlotinib(9.46 months)compared with placebo[6.37 months;hazard ratio(HR])=0.70,95%confidence interval(CI)=0.55-0.89;two-sided log-rank P=0.002].The confirmed objective response rate(ORR)was 9.2%in the anlotinib arm and 0.7%in the placebo arm.The median duration of response(DoR)was 4.83 months,with a 95%CI of 3.31-6.97 months.The toxicity profile of anlotinib was consistent with that of known anti-angiogenesis inhibitors.Common adverse drug reactions(ADRs)in anlotinib-treated patients included hypertension(67.4%),hand-foot syndrome(43.9%),hemoptysis(14.0%),thyroid stimulating hormone(TSH)elevation(46.6%),and corrected QT interval(QTc)prolongation(26.2%).Short conclusion:Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy. | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | Cancer Communications2019，39，1： | 35 |
| 2 | Aeration optimization through operation at low dissolved oxygen concentrations:Evaluation of oxygen mass transfer dynamics in different activated sludge systems显示文摘In wastewater treatment plants(WWTPs)using the activated sludge process,two methods are widely used to improve aeration efficiency — use of high-efficiency aeration devices and optimizing the aeration control strategy. Aeration efficiency is closely linked to sludge characteristics(such as concentrations of mixed liquor suspended solids(MLSS)and microbial communities)and operating conditions(such as air flow rate and operational dissolved oxygen(DO)concentrations). Moreover,operational DO is closely linked to effluent quality. This study,which is in reference to WWTP discharge class A Chinese standard effluent criteria,determined the growth kinetics parameters of nitrifiers at different DO levels in small-scale tests. Results showed that the activated sludge system could meet effluent criteria when DO was as low as 0.3 mg/L,and that nitrifier communities cultivated under low DO conditions had higher oxygen affinity than those cultivated under high DO conditions,as indicated by the oxygen half-saturation constant and nitrification ability. Based on nitrifier growth kinetics and on the oxygen mass transfer dynamic model(determined using different air flow rate(Q′_(air))and mixed liquor volatile suspended solids(MLVSS)values),theoretical analysis indicated limited potential for energy saving by improving aeration diffuser performance when the activated sludge system had low oxygen consumption; however,operating at low DO and low MLVSS could significantly reduce energy consumption. Finally,a control strategy coupling sludge retention time and MLVSS to minimize the DO level was discussed,which is critical to appropriate setting of the oxygen point and to the operation of low DO treatment technology. | Haitao Fan Lu Qi Guoqiang Liu Yuankai Zhang Qiang Fan Hongchen Wang | 2017 | Journal of Environmental Sciences2017，29，5： | 9 |
| 3 | Analysis of key microbial community during the start-up of anaerobic ammonium oxidation process with paddy soil as inoculated sludge显示文摘A sequencing batch reactor(SBR)-anaerobic ammonium oxidation(anammox) system was started up with the paddy soil as inoculated sludge. The key microbial community structure in the system along with the enrichment time was investigated by using molecular biology methods(e.g., high-throughput 16 S r RNA gene sequencing and quantitative PCR). Meanwhile,the influent and effluent water quality was continuously monitored during the whole start-up stage. The results showed that the microbial diversity decreased as the operation time initially and increased afterwards, and the microbial niches in the system were redistributed. The anammox bacterial community structure in the SBR-anammox system shifted during the enrichment, the most dominant anammox bacteria were Candidatus Jettenia. The maximum biomass of anammox bacteria achieved 1.68 × 10~9 copies/g dry sludge during the enrichment period, and the highest removal rate of TN achieved around 75%. | Xianglong Xu Guohua Liu Yuanyuan Wang Yuankai Zhang Hao Wan Lu Qi Hongchen Wang | 2018 | Journal of Environmental Sciences2018，30，2： | 8 |
| 4 | 中国国家药品监督管理局批准安罗替尼用于经两种系统化疗后疾病进展的晚期非小细胞肺癌的治疗显示文摘背景2018年5月8日,中国国家药品监督管理局(National Medical Products Administration,NMPA)批准了小分子多靶点抗血管抑制剂盐酸安罗替尼,用于既往经过至少两种系统化疗后疾病进展的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗。概要中国NMPA审查了一项随机双盲、安慰剂对照的III期临床试验,该临床试验的主要终点为总生存期(overall survival,OS)。试验共纳入437例患者随机分组(2∶1)接受安罗替尼(n=294)或安慰剂(n=143)治疗,每日1次,连服2周,停药1周。表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏感突变或间变性淋巴瘤激酶(activating anaplasticlymphomakinase,ALK)阳性的患者须经过NMPA已批准的药物治疗后出现疾病进展。安罗替尼为中国NMPA批准的用于治疗既往经过两种及以上系统化疗后疾病进展的晚期NSCLC患者的首个药物。安罗替尼组的中位OS(9.46个月)较安慰剂组[6.37个月;风险比(hazard ratio,HR)=0.70,95%置信区间(confidence Interval,CI):0.55–0.89;双侧log-rank P=0.002]显著延长。安罗替尼组的客观缓解率(objective responserate,ORR)为9.2%,安慰剂组为0.7%。安罗替尼组的中位缓解持续时间(durationofresponse,DoR)为4.83个月,95%CI为3.31–6.97个月。安罗替尼的常见不良反应(adverse drug reactions,ADRs)包括高血压(67.4%)、手足综合征(43.9%)、咳血(14.0%)、促甲状腺激素(thyroid stimulating hormone,TSH)升高(46.6%)、心电图QT间期(corrected QT Interval,QTc)延长(26.2%)。结论安罗替尼显著延长了患者的OS,可作为经二线及以上化疗后晚期或转移性非小细胞肺癌的一种新的治疗方案。 | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | 癌症2019，38，12： | 7 |
| 5 | Simple model of sludge thickening process in secondary settlers显示文摘在废水处理植物(WWTP ) ,一个第二等的定居者充当 clarifier,污泥 thickener,和污泥存储坦克在期间山峰流动因此在激活的污泥进程的性能起一个重要作用。变厚的污泥在他们的操作期间发生在第二等的 clarifiers 的更低的部分。在这研究,由从激活的污泥的完全的变厚过程检测妨碍的地区,为污泥的一个简单模型变厚的速度, u s =斧子 b (= 0.9925SSVI 3.5, b = 3.541ln (描述在妨碍的地区变厚的激活的污泥的潜力和表演的 SSVI 3.5)+12.973),被开发。然而,因为在压缩地区的污泥显示出有限变厚,在压缩地区变厚的污泥没被学习。这个实验模型用解决从四 WWTP 获得并且从第五 WWTP 用测量数据验证了更好学习污泥变厚的数据的批被开发。探索不同污泥安定和变厚的机制,污泥变厚和污泥安定的曲线被比较。最后,包括温度,激动人心的、起始的深度,和聚合物调节的几个因素能在一个生物学的反应堆导致高度集中的回来污泥和生物资源,这被发现。 | Yuankai ZHANG Hongchen WANG Lu QI Guohua LIU Zhijiang HE Songzhu JIANG | 2016 | Frontiers of Environmental Science & Engineering2016，10，2： | 3 |
| 6 | Applications of hollow nanomaterials in environmental remediation and monitoring: A review显示文摘因为他们的高化学、热的稳定性,高特定的表面区域,高孔,低密度,和好 biocompatibility,空 nanomaterials 吸引了重要注意。这些最先进的 nanomaterials 被显示了高效地吸附重金属,和不稳定的危险物质, photodegrade 坚持的器官的污染物质,和另外的混合物,并且使细菌失去活性。如此的性质为环境补习启用了这些材料的使用,例如在水 / 废水处理,土壤补习,空气纯化,并且物质监视等等。没有空结构,空 nanomaterials 由于他们的高活跃的表面区域比那些显示出更高的 photocatalytic 活动,减少了散开抵抗,并且改进了可接近性。并且,做的方法能在可见的光下面进一步改进空 nanomaterials 的 photocatalytic 表演。而且,因为他们的尺寸和形态学帮助决定他们的精确性质,这些材料的合成机制和方法是重要的。这篇文章考察环境应用和这些材料的潜在的风险,除了他们的综合体。最后,进这些材料的发展的眼界被提供。 | Yuankai ZHANG Zhijiang HE Hongchen WANG Lu QI Guohua LIU Xiaojun ZHANG | 2015 | Frontiers of Environmental Science & Engineering2015，9，5： | 2 |
| 7 | Development of a rapid and simultaneous assay for the determination of zearalenone and fumonisin BI in corn,wheat and feedstuff samples显示文摘 | WANG Yuankai SHI Yibo ZOU Qi | 2013 | Food Control2013，31，： | 1 |
| 8 | Development of a Wireless-Controlled LED Array for the Tunable Optogenetic Control of Cellular Activities显示文摘1.Introduction In order to decipher a complex biological process,tools are required to perturb the various players involved to gain information about the important parameters.Optogenetic modules are genetically encoded molecular reagents that,when expressed in cells,allow a specific biological process to be precisely controlled by light in a spatiotemporal manner[1].Optogenetics thus offers cell biologists an unprecedented new way to perturb cellular activities.The application of optogenetic approaches in cellular biology and synthetic biology research has evolved tremendously in the last few years[2–4]. | Yuankai Qi Junye Chen Xuechun Liu Xiaoxu Zhou Jiannan Fan Ping Shentu Olof Idevall-Hagren Yingke Xu | 2018 | Engineering2018，4，6： | 1 |
| 9 | Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab(2005–2018)显示文摘Background Rituximab combined with cyclophosphamide,doxorubicin hydrochloride,vincristine,and prednisone(R-CHOP)regimen has improved the survival of diffuse large B-cell lymphoma(DLBCL)patients worldwide,compared with CHOP alone.Several limitations were seen in previous studies of Chinese DLBCL patients treated with R-CHOP or R-CHOP-like regimens.This study aimed to investigate the clinical characteristics and treatment outcomes of Chinese DLBCL patients treated with the standard first-line treatment.Methods Clinical data were collected from DLBCL patients who received frontline R-CHOP or R-CHOP-like regimens at the Cancer Hospital Chinese Academy of Medical Sciences&Peking Union Medical College(CHCAMS)between January 1,2005,and December 31,2018.The treatment outcomes were compared with those of patients diagnosed with DLBCL between 2004 and 2017 and who received immunochemotherapy from the United States Surveillance,Epidemiology,and End Results(SEER)database.Survival rates were estimated using the Kaplan-Meier method and compared using the log-rank test.Multivariate analysis of progression-free survival(PFS)and overall survival(OS)was performed using Cox proportional hazard regression.Results Overall,1084 patients from the CHCAMS and 4013 patients from the SEER database were included in the study.As of April 30,2022,the median follow-up period for the CHCAMS group was 87.3(range:0.5-195.4)months.For the CHCAMS group,the 5-year PFS and OS rates were 61.7%(95%confidence interval[CI]:58.8-64.7%)and 70.6%(95%CI:67.8-73.4%),respectively.For the SEER group,the 5-year OS rate was 66.5%(95%CI:65.0-68.0%),which was inferior to that of the CHCAMS group(P<0.001).After adjusting for clinical factors and treatment,no significant difference was observed in the OS between the CHCAMS and SEER groups(P=0.867).In the CHCAMS group,multivariate analysis showed that an Eastern Cooperative Oncology Group performance status score≥2,presence of B symptoms,Ann Arbor stage III-IV,elevated serumβ2-microglobulin levels,and bulky mass were independent adverse prognostic factors affecting PFS and OS(P<0.05).Additionally,patients aged over 60 years,elevated lactate dehydrogenase levels,and more than two extranodal sites were independent adverse prognostic factors for OS(P<0.05).Local radiotherapy was significantly associated with better PFS(P<0.001)and OS(P=0.001).Conclusion After adjusting for clinical and treatment-related factors,no significant difference was observed in the 5-year OS rate between Chinese DLBCL patients treated with standard first-line treatment and those from the SEER database. | Yuankai Shi Haizhu Chen Yan Qin Jianliang Yang Peng Liu Xiaohui He Shengyu Zhou Liqiang Zhou Changgong Zhang Yongwen Song Yueping Liu Lin Gui Shulian Wang Jing Jin Hui Fang Shunan Qi Ning Li Yu Tang Xin Wang Sheng Yang | 2023 | Cancer Pathogenesis and Therapy2023，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员